Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CHRONIC-SCHIZOPHRENIC PATIENTS' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 122 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Peuskens, J; De Hert, M; Jones, M
      The clinical value of risperidone and olanzapine: A meta-analysis of efficacy and safety

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    2. Shermock, KM; Sadik, MK; Kozma, CM; Sesti, AM; Reeder, CE
      Risperidone, haloperidol and clozapine in the South Carolina Medicaid program - A comparative analysis of utilisation and expenditure

      DISEASE MANAGEMENT & HEALTH OUTCOMES
    3. Jacus, JP; Martin, C; Ailleret-Jean, C; Courcet, L; Delmotte-Tsocanakis, G; Faraldi, O; Hamon-Vilcot, B; Heurteux, V; Labram, A; Lutzler, P; Planques, B; Rethore, V; Trivalle, C; Fremont, P
      The cognitive aging of psychotic patients

      PRESSE MEDICALE
    4. Wykes, T; van der Gaag, M
      Is it time to develop a new cognitive therapy for psychosis - Cognitive remediation therapy (CRT)?

      CLINICAL PSYCHOLOGY REVIEW
    5. Potkin, SG; Fleming, K; Jin, Y; Gulasekaram, B
      Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    6. Kane, J
      Progress defined - short-term efficacy, long-term effectiveness

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    7. Meirik, K; Linaker, OM
      Factors that influence self-reported compliance for neuroleptics

      EUROPEAN JOURNAL OF PSYCHIATRY
    8. Fleischhacker, WW; Lemmens, P; van Baelen, B
      A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database

      PHARMACOPSYCHIATRY
    9. Shepherd, AJ
      Increased visual after-effects following pattern adaptation in migraine: alack of intracortical excitation?

      BRAIN
    10. Procyshyn, RM; Thompson, D; Tse, G
      Pharmacoeconomics of clozapine, risperidone and olanzapine - A review of the literature

      CNS DRUGS
    11. Masand, PS; Berry, SL
      Switching antipsychotic therapies

      ANNALS OF PHARMACOTHERAPY
    12. Mohr, E; Mendis, T; Hildebrand, K; De Deyn, PP
      Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial

      MOVEMENT DISORDERS
    13. Al-Sughayir, MA
      Depot antipsychotics - Patient characteristics and prescribing pattern

      SAUDI MEDICAL JOURNAL
    14. Marsalek, M
      Tardive drug-induced extrapyramidal syndromes

      PHARMACOPSYCHIATRY
    15. Horacek, J
      Novel antipsychotics and extrapyramidal side effects. Theory and reality

      PHARMACOPSYCHIATRY
    16. Martinez-Aran, A; Vieta, E; Colom, F; Reinares, M; Benabarre, A; Gasto, C; Salamero, M
      Cognitive dysfunctions in bipolar disorder: Evidence of neuropsychologicaldisturbances

      PSYCHOTHERAPY AND PSYCHOSOMATICS
    17. McNeil, DC; Reddon, JR
      Utility and stability of the Basic Personality Inventory in psychiatric patients with longstanding psychotic disorders in a new Psychiatric Rehabilitation program over a two-year period

      PSYCHOLOGICAL REPORTS
    18. Lambert, M; Moritz, S; Haasen, C; Naber, D
      Conversion from conventional to atypical neuroleptics - recommendations for inpatient and outpatient treatment

      NERVENARZT
    19. Kumar, AM; Fernandez, JB; Schneiderman, N; Goodkin, K; Eisdorfer, C; Kumar, M
      Simultaneous determination of 5-hydroxytryptaminie, 5-hydroxytryptophan, 5-hydroxyindoleacetic acid, dopamine, and homovanillic acid in whole blood, using isocratic HPLC with electrochemical detection

      JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
    20. Megna, JL; Dewan, M
      A naturalistic study of risperidone maintenance treatment of outpatients with severe mental illness

      PSYCHIATRIC SERVICES
    21. Brown, CS; Markowitz, JS; Moore, TR; Parker, NG
      Atypical antipsychotics: Part II - Adverse effects, drug interactions, andcosts

      ANNALS OF PHARMACOTHERAPY
    22. Hammond, CM; Pierson, JF; Grande, TP; Munetz, MR; Wilson, DR; Pathak, DS
      Economic evaluation of risperidone in an outpatient population

      ANNALS OF PHARMACOTHERAPY
    23. Markowitz, JS; Brown, CS; Moore, TR
      Atypical antipsychotics - Part I: Pharmacology, pharmacokinetics, and efficacy

      ANNALS OF PHARMACOTHERAPY
    24. Moller, HJ
      Atypical neuroleptics: a new approach in the treatment of negative symptoms

      EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
    25. Hayashi, T; Su, TP; Kagaya, A; Nishida, A; Shimizu, M; Yamawaki, S
      Neuroleptics with differential affinities at dopamine D-2 receptors and sigma receptors affect differently the N-methyl-D-aspartate-induced increase in intracellular calcium concentration: Involvement of protein kinase

      SYNAPSE
    26. Tkachuk, GA; Martin, GL
      Exercise therapy for patients with psychiatric disorders: Research and clinical implications

      PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE
    27. Olbrich, R
      Psychological methods for reduction of cognitive deficits - Experiences with a computer-based training program

      FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
    28. Callicott, JH; Weinberger, DR
      Neuropsychiatric dynamics: the study of mental illness using functional magnetic resonance imaging

      EUROPEAN JOURNAL OF RADIOLOGY
    29. Dickson, RA; Dalby, JT; Addington, D; Williams, R; McDougall, GM
      Hospital days in risperidone-treated patients

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    30. Spaulding, WD; Reed, D; Sullivan, M; Richardson, C; Weiler, M
      Effects of cognitive treatment in psychiatric rehabilitation

      SCHIZOPHRENIA BULLETIN
    31. Coley, KC; Carter, CS; DaPos, SV; Maxwell, R; Wilson, JW; Branch, RA
      Effectiveness of antipsychotic therapy in a naturalistic setting: A comparison between risperidone, perphenazine, and haloperidol

      JOURNAL OF CLINICAL PSYCHIATRY
    32. Maixner, SM; Mellow, AM; Tandon, R
      The efficacy, safety, and tolerability of antipsychotics in the elderly

      JOURNAL OF CLINICAL PSYCHIATRY
    33. Galvin, PM; Knezek, LD; Rush, AJ; Toprac, MG; Johnson, R
      Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center

      CLINICAL THERAPEUTICS
    34. Malla, AK; Norman, RMG; Kotteda, V; Zirul, S
      Switching from therapy with typical antipsychotic agents to risperidone: Long-term impact on patient outcome

      CLINICAL THERAPEUTICS
    35. Hertel, P; Nomikos, GG; Svensson, TH
      The antipsychotic drug risperidone interacts with auto- and hetero-receptors regulating serotonin output in the rat frontal cortex

      NEUROPHARMACOLOGY
    36. Ossowska, K; Pietraszek, M; Wardas, J; Nowak, G; Wolfarth, S
      Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats

      NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
    37. Sajatovic, M; Ramirez, LF; Belton, J; McCormick, R
      Health resource utilization and clinical outcomes with risperidone therapyin patients with serious mental illness

      COMPREHENSIVE PSYCHIATRY
    38. McGorry, PD; McConville, SB
      Insight in psychosis: An elusive target

      COMPREHENSIVE PSYCHIATRY
    39. Conley, RR; Love, RC; Kelly, DL; Bartko, JJ
      Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine

      AMERICAN JOURNAL OF PSYCHIATRY
    40. Lemmens, P; Brecher, M; Van Baelen, B
      A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms

      ACTA PSYCHIATRICA SCANDINAVICA
    41. Kampman, O; Lehtinen, K
      Compliance in psychoses

      ACTA PSYCHIATRICA SCANDINAVICA
    42. RENERIC JP; BOUVARD MP
      OPIOID RECEPTOR IN ANTAGONISTS IN PSYCHIATRY - BEYOND DRUG-ADDICTION

      CNS drugs
    43. REVICKI DA; PALMER C
      UNTITLED - AUTHORS REPLY

      American journal of managed care
    44. NIGHTENGALE BS; GARRETT L; WAUGH S; LAWRENCE BJ; ANDRUS J
      ECONOMIC OUTCOMES ASSOCIATED WITH THE USE OF RISPERIDONE IN A NATURALISTIC GROUP-PRACTICE SETTING

      American journal of managed care
    45. LOEBEL AD; BOTTS SR; FELDMAN BI
      ATYPICAL ANTIPSYCHOTICS IN THE MANAGED CARE ERA

      American journal of managed care
    46. ZIPURSKY RB; ZHANGWONG JH; LAMBE EK; BEAN G; BEISER M
      MRI CORRELATES OF TREATMENT RESPONSE IN FIRST EPISODE PSYCHOSIS

      Schizophrenia research
    47. HAMILTON SH; REVICKI DA; GENDUSO LA; BEASLEY CM
      OLANZAPINE VERSUS PLACEBO AND HALOPERIDOL - QUALITY-OF-LIFE AND EFFICACY RESULTS OF THE NORTH-AMERICAN DOUBLE-BLIND TRIAL

      Neuropsychopharmacology
    48. ULRICH S; WURTHMANN C; BROSZ M; MEYER FP
      THE RELATIONSHIP BETWEEN SERUM CONCENTRATION AND THERAPEUTIC EFFECT OF HALOPERIDOL IN PATIENTS

      Clinical pharmacokinetics
    49. HERTEL P; LINDBLOM N; NOMIKOS GG; SVENSSON TH
      MODULATION OF CENTRAL SEROTONERGIC NEUROTRANSMISSION BY RISPERIDONE -UNDERLYING MECHANISM[S] AND SIGNIFICANCE OF ACTION

      Progress in neuro-psychopharmacology & biological psychiatry
    50. Kinon, BJ
      The routine use of atypical antipsychotic agents: Maintenance treatment

      JOURNAL OF CLINICAL PSYCHIATRY
    51. CARTER C; STEVENS M; DURKIN M
      EFFECTS OF RISPERIDONE THERAPY ON THE USE OF MENTAL-HEALTH-CARE RESOURCES IN SALT-LAKE-COUNTY, UTAH

      Clinical therapeutics
    52. DAVIES A; LANGLEY PC; KEKS NA; CATTS SV; LAMBERT T; SCHWEITZER I
      RISPERIDONE VERSUS HALOPERIDOL - II - COST-EFFECTIVENESS

      Clinical therapeutics
    53. KIRALY SJ; GIBSON RE; ANCILL RJ; HOLLIDAY SG
      RISPERIDONE - TREATMENT RESPONSE IN ADULT AND GERIATRIC-PATIENTS

      International journal of psychiatry in medicine
    54. Finley, PR; Sommer, BR; Corbitt, JL; Brunson, GH; Lum, BL
      Risperidone: Clinical outcome predictors and cost-effectiveness in a naturalistic setting

      PSYCHOPHARMACOLOGY BULLETIN
    55. Ganguli, R; Brar, JS
      The effects of risperidone and olanzapine on the indications for clozapine

      PSYCHOPHARMACOLOGY BULLETIN
    56. ALMOND DS; RHODES LE; PIRMOHAMED M
      RISPERIDONE-INDUCED PHOTOSENSITIVITY

      Postgraduate medical journal
    57. DERUBEIS RJ; CRITSCHRISTOPH P
      EMPIRICALLY SUPPORTED INDIVIDUAL AND GROUP PSYCHOLOGICAL TREATMENTS FOR ADULT MENTAL-DISORDERS

      Journal of consulting and clinical psychology
    58. OLESEN OV; LINNET K
      SIMPLIFIED HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR DETERMINATION OF RISPERIDONE AND 9-HYDROXYRISPERIDONE IN SERUM FROM PATIENTS COMEDICATED WITH OTHER PSYCHOTROPIC-DRUGS

      Journal of chromatography B. Biomedical sciences and applications
    59. TAYLOR D
      SWITCHING FROM TYPICAL TO ATYPICAL ANTIPSYCHOTICS - PRACTICAL GUIDELINES

      CNS DRUGS
    60. STEFANSKI R; GOLDBERG SR
      SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS - POTENTIAL IN THE TREATMENT OF PSYCHIATRIC-DISORDERS

      CNS DRUGS
    61. HOLLOMAN LC; MARDER SR
      MANAGEMENT OF ACUTE EXTRAPYRAMIDAL EFFECTS INDUCED BY ANTIPSYCHOTIC-DRUGS

      American journal of health-system pharmacy
    62. RICE ME; HARRIS GT
      THE TREATMENT OF MENTALLY DISORDERED OFFENDERS

      Psychology, public policy, and law
    63. VIALE G; MECHLING L; MAISLIN G; DURKIN M; ENGELHART L; LAWRENCE BJ
      IMPACT OF RISPERIDONE ON THE USE OF MENTAL-HEALTH-CARE RESOURCES

      Psychiatric services
    64. CASTELLANOS FX
      NEUROIMAGING OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER

      Child and adolescent psychiatric clinics of North America
    65. WALTERS VL; TOGNOLINI RZ; RUEDA HM; RUEDA RM; TORRES RG
      NEW STRATEGIES FOR OLD PROBLEMS - TARDIVE-DYSKINESIA (TD) - REVIEW AND REPORT ON SEVERE TD CASES TREATED WITH CLOZAPINE, WITH 12, 8 AND 5 YEARS OF VIDEO FOLLOW-UP

      Schizophrenia research
    66. SCHOOLER NR
      NEW-ANTIPSYCHOTIC MEDICATIONS - STRATEGIES FOR EVALUATION AND SELECTED FINDINGS

      Schizophrenia research
    67. HERTEL P; NOMIKOS GG; SCHILSTROM B; ARBORELIUS L; SVENSSON TH
      RISPERIDONE DOSE-DEPENDENTLY INCREASES EXTRACELLULAR CONCENTRATIONS OF SEROTONIN IN THE RAT FRONTAL-CORTEX - ROLE OF ALPHA(2)-ADRENOCEPTOR ANTAGONISM

      Neuropsychopharmacology
    68. MATTES JA
      RISPERIDONE - HOW GOOD IS THE EVIDENCE FOR EFFICACY

      Schizophrenia bulletin
    69. GUTIERREZ R; LEE PID; HUANG ML; WOESTENBORGHS R
      RISPERIDONE - EFFECTS OF FORMULATIONS ON ORAL BIOAVAILABILITY

      Pharmacotherapy
    70. GUTIERREZESTEINOU R; GREBB JA
      RISPERIDONE - AN ANALYSIS OF THE FIRST 3 YEARS IN GENERAL USE

      International clinical psychopharmacology
    71. WEIDEN PJ; AQUILA R; DALHEIM L; STANDARD JM
      SWITCHING ANTIPSYCHOTIC MEDICATIONS

      The Journal of clinical psychiatry
    72. AMADOR XF; SECKINGER RA
      THE ASSESSMENT OF INSIGHT - A METHODOLOGICAL REVIEW

      Psychiatric annals
    73. HERTEL P; NOMIKOS GG; SVENSSON TH
      RISPERIDONE INHIBITS 5-HYDROXYTRYPTAMINERGIC NEURONAL-ACTIVITY IN THEDORSAL RAPHE NUCLEUS BY LOCAL RELEASE OF 5-HYDROXYTRYPTAMINE

      British Journal of Pharmacology
    74. VANOS J; FAHY T; JONES P; HARVEY I; TOONE B; MURRAY R
      TARDIVE-DYSKINESIA - WHO IS AT RISK

      Acta psychiatrica Scandinavica
    75. DENCKER SJ; AXELSSON R
      OPTIMIZING THE USE OF DEPOT ANTIPSYCHOTICS

      CNS DRUGS
    76. BARNES TRE; MCPHILLIPS MA
      ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SYMPTOMS - ROLE OF ANTICHOLINERGIC DRUGS IN TREATMENT

      CNS DRUGS
    77. REMINGTON G; BEZCHLIBNYKBUTLER K
      MANAGEMENT OF ACUTE ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SYNDROMES

      CNS DRUGS
    78. BUCKLEY PF; SCHULZ SC
      CLOZAPINE AND RISPERIDONE - REFINING AND EXTENDING THEIR USE

      Harvard review of psychiatry
    79. OLBRICH R
      COMPUTER-BASED PSYCHIATRIC REHABILITATION - CURRENT ACTIVITIES IN GERMANY

      European psychiatry
    80. SILVER H; GERAISY N
      ON PRESCRIBING AN ANTIPARKINSONIAN DRUG

      Human psychopharmacology
    81. UMBRICHT D; KANE JM
      MEDICAL COMPLICATIONS OF NEW ANTIPSYCHOTIC-DRUGS

      Schizophrenia bulletin
    82. JANN MW; WEI FC; LIN HN; CHING PC; CHANG WH
      HALOPERIDOL AND REDUCED HALOPERIDOL PLASMA-CONCENTRATIONS AFTER A LOADING DOSE REGIMEN WITH HALOPERIDOL DECANOATE

      Progress in neuro-psychopharmacology & biological psychiatry
    83. RALEIGH F
      USE OF NOVEL ANTIPSYCHOTIC-DRUGS

      Pharmacotherapy
    84. BYERLY MJ; DEVANE CL
      PHARMACOKINETICS OF CLOZAPINE AND RISPERIDONE - A REVIEW OF RECENT LITERATURE

      Journal of clinical psychopharmacology
    85. MARDER SR
      CLINICAL-EXPERIENCE WITH RISPERIDONE

      The Journal of clinical psychiatry
    86. HARGREAVES WA; SHUMWAY M
      PHARMACOECONOMICS OF ANTIPSYCHOTIC DRUG-THERAPY

      The Journal of clinical psychiatry
    87. MEYER MC; BALDESSARINI RJ; GOFF DC; CENTORRINO F
      CLINICALLY SIGNIFICANT INTERACTIONS OF PSYCHOTROPIC AGENTS WITH ANTIPSYCHOTIC-DRUGS

      Drug safety
    88. KIMURA M; MEYER JM; SIMPSON GM
      ANTICHOLINERGIC PROPHYLAXIS REVISITED

      Psychiatric annals
    89. DAVIS JM; JANICAK PG
      RISPERIDONE - A NEW, NOVEL (AND BETTER) ANTIPSYCHOTIC

      Psychiatric annals
    90. DILK MN; BOND GR
      METAANALYTIC EVALUATION OF SKILLS TRAINING RESEARCH FOR INDIVIDUALS WITH SEVERE MENTAL-ILLNESS

      Journal of consulting and clinical psychology
    91. OWENS DGC
      ADVERSE-EFFECTS OF ANTIPSYCHOTIC AGENTS - DO NEWER AGENTS OFFER ADVANTAGES

      Drugs
    92. BORISON RL
      THE ROLE OF COGNITION IN THE RISK-BENEFIT AND SAFETY ANALYSIS OF ANTIPSYCHOTIC MEDICATION

      Acta psychiatrica Scandinavica
    93. MELTZER HY; LEE MA; RANJAN R; MASON EA; COLA PA
      RELAPSE FOLLOWING CLOZAPINE WITHDRAWAL - EFFECT OF NEUROLEPTIC DRUGS AND CYPROHEPTADINE

      Psychopharmacology
    94. CORRIGAN PW; PENN DL
      THE EFFECTS OF ANTIPSYCHOTIC AND ANTIPARKINSONIAN MEDICATION ON PSYCHOSOCIAL SKILL LEARNING

      Clinical psychology
    95. MUESER KT; WALLACE CJ; LIBERMAN RP
      NEW DEVELOPMENTS IN SOCIAL SKILLS TRAINING

      Behaviour change
    96. DEOLIVEIRA IR; DARDENNES RM; AMORIM ES; DIQUET B; DESENA EP; MOREIRA EC; DECASTROESILVA EJ; PAYAN C; FERMANIAN J; MARCILIO C; SAMUELLAJEUNESSE B
      IS THERE A RELATIONSHIP BETWEEN ANTIPSYCHOTIC BLOOD-LEVELS AND THEIR CLINICAL EFFICACY - AN ANALYSIS OF STUDIES DESIGN AND METHODOLOGY

      Fundamental and clinical pharmacology
    97. GUAY DRP
      THE EMERGING ROLE OF VALPROATE IN BIPOLAR DISORDER AND OTHER PSYCHIATRIC-DISORDERS

      Pharmacotherapy
    98. HUTTUNEN M
      THE EVOLUTION OF THE SEROTONIN-DOPAMINE ANTAGONIST CONCEPT

      Journal of clinical psychopharmacology
    99. BEBBINGTON PE
      THE CONTENT AND CONTEXT OF COMPLIANCE

      International clinical psychopharmacology
    100. GERLACH J; PEACOCK L
      NEW ANTIPSYCHOTICS - THE PRESENT STATUS

      International clinical psychopharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/12/19 alle ore 01:18:47